SKYRIZI REAL
PATIENT STORIES

MARIANN: My name is Mariann, and I have moderate to severe UC.

SUPER: MARIANN
A REAL ULCERATIVE COLITIS PATIENT

MARIANN: I absolutely refused to accept the fact that I had the diagnosis. I talked with the doctor. I assured her that it was simply the stress that I was going through at the time. We were moving. I was retiring. There was a lot happening in my life.

MARIANN: When the symptoms started, it was simply diarrhea every now and then. That quickly escalated to quite often. Then, because of the ulcers, I started to bleed along with it.

MARIANN: At my worst, I was having 15 to 20 bowel movements a day.

MARIANN: My doctor put me on a treatment after I was diagnosed.

MARIANN: The treatment lessened the number of times that I ran to the bathroom during the day.

MARIANN: There was slight improvement, and then it just stagnated.

MARIANN: Even though the doctors were telling me that the medication wasn’t working as well as they felt it should, I didn’t want to give it up.

MARIANN: My UC symptoms had been so disruptive, that I was hesitant to let go of one treatment to start another.

MARIANN: But my gastroenterologist really encouraged me to try SKYRIZI.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: SKYRIZI is a prescription medicine used to treat moderate to severe ulcerative colitis in adults. Please see Important Safety Information near the end of this video.

MARIANN: When deciding if SKYRIZI was right for me, my doctor and I discussed both the potential side effects and benefits.

LEGAL SUPER: SKYRIZI is a prescription medicine used to treat moderate to severe ulcerative colitis in adults. Please see Important Safety Information near the end of this video.

MARIANN: I knew after the first treatment, so at the end of the first four weeks, that I felt better.

SUPER: After 4 weeks of SKYRIZI, I FELT BETTER

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief, including fewer bowel movements and bloody stools, as early as 4 weeks.

MARIANN: I had fewer trips to the bathroom. I had less bleeding.

SUPER: Fewer trips to the BATHROOM and LESS BLEEDING

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief, including fewer bowel movements and bloody stools, as early as 4 weeks.

MARIANN: I didn’t feel like I needed to carry a change of clothes with me.

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief, including fewer bowel movements and bloody stools, as early as 4 weeks.

MARIANN: If I could go back in time, I wish I would have taken my doctor’s advice sooner.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: Please keep watching for Important Safety Information.

VO/SUPER:

USE AND IMPORTANT SAFETY INFORMATION

SKYRIZI^® (risankizumab-rzaa) USE

SKYRIZI is a prescription medicine used to treat moderate to severe ulcerative colitis in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
  • fainting, dizziness, feeling lightheaded (low blood pressure)
  • swelling of your face, eyelids, lips, mouth, tongue, or throat
  • trouble breathing or throat tightness
  • chest tightness
  • skin rash, hives
  • itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  • fever, sweats, or chills
  • cough
  • shortness of breath
  • blood in your mucus (phlegm)
  • muscle aches
  • warm, red, or painful skin or sores on your body different from your psoriasis
  • weight loss
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?”

Liver problems may happen while being treated for Crohn’s disease or ulcerative colitis: A person with Crohn’s disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 600 mg/10 mL vial for intravenous infusion and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

© 2025 AbbVie. All rights reserved.

SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.

US-SKZG-250040